Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for platinum-resistant or refractory ovarian cancer
ChiCTR2000029654Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Mar 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2000029654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029654.